Clinical Trials Browser

Phase 1/2 × Azacitidine × Plasma cell × Clear all

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT01155583 2020-11-16

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

45 enrolled 20 charts

Plasma cell

Multiple Myeloma

Clinical Trials

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma